drugset / Trial / NCT04223661
Frailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction Therapy
Phase 2
Withdrawn
Attaya Suvannasankha
Indiana Institute for Medical Research · collabJanssen Scientific Affairs, LLC · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine if using a subject's baseline frailty score to guide the dosing of lenalidomide in a combination with dexamethasone and daratumumab (DRd lite).
Timeline
- Start
- 2021-12-06
- Primary completion
- 2022-12-31
- Completion
- 2023-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenalidomide | Other / unclassified | 10 mg | Oral |
| Subject | Lenalidomide | Other / unclassified | 15 mg | Oral |
| Background | Daratumumab | Monoclonal antibody | 1800 mg | Subcutaneous |
| Background | Dexamethasone | Small molecule | 20 mg | Intravenous |